Company news

Ionis Pharmaceuticals, Inc. news in 2023

Ionis Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.

View company

WAINUA™ (eplontersen) granted regulatory approval in the U.S. for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis

December 20, 2023

Ionis to present at 42nd Annual J.P. Morgan Healthcare Conference

December 19, 2023

Ionis announces European licensing agreement with Otsuka for donidalorsen in hereditary angioedema

December 17, 2023

Ionis announces the appointment of Michael Yang to Board of Directors

December 13, 2023

Ionis shares positive clinical update from ongoing trial of ION582 for Angelman syndrome

November 10, 2023

Ionis presents positive two-year results from the Phase 2 open label extension study of donidalorsen in patients with hereditary angioedema

November 8, 2023

Ionis reports third quarter 2023 financial results

November 1, 2023

Ionis to hold third quarter 2023 financial results webcast

October 18, 2023

Ionis shares significant business and pipeline progress at Innovation Day, highlighting strength of capabilities from research and technology through commercialization

October 3, 2023

Eplontersen Phase 3 results published in JAMA show consistent and sustained benefit

September 27, 2023

Ionis enters agreement with Roche for two novel RNA-targeted programs for Alzheimer's disease and Huntington's disease

September 26, 2023

Ionis announces positive olezarsen topline results from Phase 3 study in people with familial chylomicronemia syndrome

September 25, 2023

Ionis to host investor and analyst day event

September 11, 2023

Ionis reports second quarter 2023 financial results

August 8, 2023

Ionis enters collaboration to advance next generation program targeting Lp(a) for cardiovascular disease

August 2, 2023

Ionis completes enrollment in landmark Phase 3 CARDIO-TTRansform study in patients with TTR-mediated amyloid cardiomyopathy

July 30, 2023

Ionis expands eplontersen agreement with AstraZeneca to include exclusive rights in Latin America

July 27, 2023

Ionis to hold second quarter 2023 financial results webcast

July 25, 2023

Eplontersen continued to show improvement in ATTRv-PN through 85 weeks

July 9, 2023

Ionis to present at upcoming investor conference

July 4, 2023

Ionis prices private placement of convertible senior notes

June 6, 2023

Ionis announces proposed private placement of convertible notes

June 5, 2023

Ionis announces positive donidalorsen late-stage clinical progress in HAE

May 31, 2023

Ionis to host 2023 virtual Annual Meeting of Stockholders

May 9, 2023

Ionis reports first quarter 2023 financial results

May 2, 2023

FDA approves QALSODY™ (tofersen) as the first treatment targeting a genetic cause of ALS

April 24, 2023

Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks

April 23, 2023

Ionis to hold first quarter 2023 financial results webcast

April 19, 2023

New data presented at AD/PD™2023 show IONIS-MAPT Rx (BIIB080) substantially reduced tau protein in patients with early-stage Alzheimer's disease

March 28, 2023

Ionis reports positive topline 66-week results of eplontersen Phase 3 study for patients with ATTRv-PN

March 26, 2023

Ionis accounces FDA advisory committee voted unanimously for a potential accelerated approval of tofersen for SOD1-ALS

March 21, 2023

Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)

March 6, 2023

Ionis reports fourth quarter and full year 2022 financial results

February 21, 2023

Ionis announces new donidalorsen data and presentations at the 2023 American Academy of Allergy, Asthma & Immunology Annual Meeting

February 20, 2023

Ionis to hold fourth quarter and full year 2022 financial results webcast

February 7, 2023

Ionis announces GSK has advanced bepirovirsen into Phase 3 development

January 31, 2023

Ionis receives FDA Fast Track designation for olezarsen in patients with familial chylomicronemia syndrome

January 30, 2023

Ionis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease Research

January 25, 2023

Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness

January 8, 2023

Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness

January 8, 2023

Ionis to present at 41st Annual J.P. Morgan Healthcare conference

January 3, 2023

Calls in 2023

Decks in 2023